Brief: Aim Immunotech Receives Erasmus Medical Center Ethics Board Authorization For Phase 2 Study Of Ampligen® For The Treatment Of Locally Advanced Pancreatic Cancer
24/01/2024 16:27
Jan 24 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH RECEIVES ERASMUS MEDICAL CENTER ETHICS
BOARD
AUTHORIZATION FOR PHASE 2 STUDY OF AMPLIGEN® FOR THE TREATMENT
OF LOCALLY ADVANCED PANCREATIC CANCER
Source text for Eikon: ID:nGNX807CdG
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential